Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its on